ROIV Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of --. Roivant Sciences's return on equity of -1.94% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Roivant Sciences has a consensus price target of $16.75, signalling upside risk potential of 51.86%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1172.62%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Roivant Sciences, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Roivant Sciences.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $9M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Roivant Sciences's net income of $169.4M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Roivant Sciences's price-to-earnings ratio is 1.91x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 50.22x versus 1.47x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Immunovant has a net margin of -5143.78% compared to Roivant Sciences's net margin of --. Roivant Sciences's return on equity of -1.94% beat Immunovant's return on equity of --.

Roivant Sciences has a consensus price target of $16.75, signalling upside risk potential of 51.86%. On the other hand Immunovant has an analysts' consensus of $45.15 which suggests that it could grow by 215.76%. Given that Immunovant has higher upside potential than Roivant Sciences, analysts believe Immunovant is more attractive than Roivant Sciences.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunovant has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.634%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Immunovant pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $9M, which are larger than Immunovant quarterly revenues of --. Roivant Sciences's net income of $169.4M is higher than Immunovant's net income of -$111.1M. Notably, Roivant Sciences's price-to-earnings ratio is 1.91x while Immunovant's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 50.22x versus -- for Immunovant. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of --. Roivant Sciences's return on equity of -1.94% beat NuCana PLC's return on equity of --.

Roivant Sciences has a consensus price target of $16.75, signalling upside risk potential of 51.86%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 100969%. Given that NuCana PLC has higher upside potential than Roivant Sciences, analysts believe NuCana PLC is more attractive than Roivant Sciences.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $9M, which are larger than NuCana PLC quarterly revenues of --. Roivant Sciences's net income of $169.4M is higher than NuCana PLC's net income of -$836.1K. Notably, Roivant Sciences's price-to-earnings ratio is 1.91x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 50.22x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of -21.4%. Roivant Sciences's return on equity of -1.94% beat Verona Pharma PLC's return on equity of -85.84%.

Roivant Sciences has a consensus price target of $16.75, signalling upside risk potential of 51.86%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 42.02%. Given that Roivant Sciences has higher upside potential than Verona Pharma PLC, analysts believe Roivant Sciences is more attractive than Verona Pharma PLC.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $9M, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Roivant Sciences's net income of $169.4M is higher than Verona Pharma PLC's net income of -$16.3M. Notably, Roivant Sciences's price-to-earnings ratio is 1.91x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 50.22x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.